Comparative Urine Proteomic Studies of Overactive Bladder in Humans

Washington University School of Medicine21 enrolled

Overview

This study is being done to evaluate the use of a new technology (urine proteomics) - the study of proteins in the urine to identify urine markers of overactive bladder (OAB) from a simple voided urine specimen.

The objectives of the study are: 1. to improve the diagnosis of overactive bladder using a non-invasive technology (urine proteomics) and 2. to study how potential urine biomarkers changes with overactive bladder symptoms after patients have been treated with fesoterodine, an FDA approved drug for the treatment of overactive bladder.

Study Type

INTERVENTIONAL

Allocation

Masking

NONE

Enrollment

Conditions

Overactive Bladder

Interventions

fesoterodineDRUG

Fesoterodine 4 mg. tablet by mouth daily for six weeks

Eligibility

Sex: FEMALEMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: For healthy volunteers the inclusion criteria are: 1. Females ≥ 18 years old 2. Not experiencing overactive bladder symptoms 3. Not experiencing frequency or urgency For overactive bladder patients the inclusion criteria are 1. Females ≥ 18 years old 2. Overactive bladder symptoms for ≥ 3 months before screening ) Recurrent urinary tract infections (UTIS) \> 3/year Exclusion Criteria: For healthy volunteers the exclusion criteria are: 1. Overactive bladder symptoms, such as frequency and urgency 2. Intermittent/unstable use of bladder medications 3. Pregnant women or women unwilling to use contraceptives 4. Neurological conditions: stroke, Multiple Sclerosis (MS), Parkinson's, spinal cord injury 5. Significant pelvic organ prolapsed (grade 3 or above based on physical exam) 6. Lower urinary tract surgery within past 6 months 7. Known history of IC or pain associated with OAB 8. Urinary retention requiring catheterization, indwelling catheter of Self-cath 9. Recurrent UTIS \> 3/year For overactive bladder patients the exclusion criteria are: 1. Contraindications to Fesoterodine use such as hypersensitivity, GI and urinary retention, and Glaucoma 2. Intermittent/unstable use of bladder medications 3. Pregnant women or women unwilling to use contraceptives 4. Neurological conditions: stroke, MS, Parkinson's, spinal cord injury 5. Significant pelvic organ prolapsed (grade 3 or above based on physical exam) 6. Lower urinary tract surgery within past 6 months 7. Known history of Interstitial Cystitis (IC) or pain associated with OAB 8. Urinary retention requiring catheterization, indwelling catheter of Self-cath 9. Recurrent urinary tract infections (UTIS) \> 3/year Deferral Criteria: Treatment with OAB medications within 2 weeks before baseline visit. If patient is currently on OAB medications the patient will be asked to stop OAB medication for 2 weeks and return for baseline visit.

Locations (1)

Washington University School of Medicine

St Louis, Missouri, United States

Outcomes

Primary Outcomes

Bladder Diary to Assess Urinary Frequency at Baseline and at End of 6-week Treatment

Overactive bladder subjects filled out a 3-day bladder diary before starting Fesoterodine and another 3-day bladder diary at the end of taking 6 weeks of Fesoterodine. The bladder diary was used to assess urinary frequency. The average number of urinations (frequency) per day over a period of 3 days before the start of medication and at the end of 6 weeks of medication were compared for each subject and then as a group.

Time frame: Outcome measure was assessed at baseline and at the end of the 6-week treatment

Bladder Diary (Using Urinary Sensation Scale Found in Bladder Diary) to Assess Urinary Urgency at Baseline and at 6-week Treatment

The Urinary Sensation Scale found in the bladder diary given to subjects was used to assess urinary urgency. The Urinary Sensation Scale was filled out by the subject for 3 days before starting Fesoterodine and filled out again for 3 days at the end of taking 6 weeks of Fesoterodine. The scale ranges from 1 (no feeling of urgency), 2 (mild), 3 (moderate), 4 (severe) to 5 (unable to hold; leak urine). The urgency scale with the most check marks per day over a period of 3 days before start of medication was averaged for each subject. The urgency scale with the most check marks per day over a period of 3 days at the end of taking 6 weeks of medication was averaged for each subject. Then, the average before start of medication for all subjects and the average at the end of taking 6 weeks of medication for all subjects were compared.

Time frame: Outcome measure was assesses at baseline and at the end of the 6-week treatment period.

Secondary Outcomes

Overactive Bladder Questionnaire (OAB-q) to Assess Bother From Urinary Frequency at Baseline and at 6 Weeks.

Overactive Bladder subjects answered the Overactive Bladder Questionnaire (OAB-q) before starting Fesoterodine and at the end of taking 6 weeks of Fesoterodine. The OAB-q consists of 8 questions asking how bothered subject was in the past 4 weeks. Questions # 1 (Frequent urination during the daytime hours?); #5 (Nighttime urination?) and #6 (Waking up at night because you have to urinate?) are asking about frequency. Choices of answers are: 1 (Not at all); 2 (A little bit); 3 (Somewhat); 4 (Quite a bit); 5 (A great deal) 6 (A very great deal). Multiple responses to the questionnaire were averaged for each participant at baseline and at 6 weeks and then all participants' answers were totaled and averaged at baseline and at 6 weeks.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.